Compare IAC/Interactivecorp (PPLI) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IAC/Interactivecorp vs Regeneron Pharmaceuticals Inc — how do they compare? IAC/Interactivecorp trades at $40.94 (market cap $3.02B), while Regeneron Pharmaceuticals Inc trades at $737.72 (market cap $76.40B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 25.3× IAC/Interactivecorp's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while IAC/Interactivecorp pays none. Which is the better fit depends on your goals — on Pluang, investors hold IAC/Interactivecorp for 79 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| PPLI | REGN | |
|---|---|---|
Market Cap | $3.02B | $76.40B |
Volume | 932,191 | 626,381 |
Sector | Media | Health |
52-Week High | $47.62 | $852.03 |
52-Week Low | $31.52 | $557.73 |
Typical Hold Time | 79 Days | 107 Days |
Enterprise Value | $3.51B | $71.12B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPLI trades at $40.93, down 0.87% on the day, with strong analyst support (71% buy ratings) amid MGM acquisition speculation. The stock shows bullish technical momentum with recent earnings volatility, including a significant Q2 2026 beat. Fundamentals reveal mixed performance with negative 2025 net income but improving 2026 projections, while valuation metrics appear attractive with P/E of 6.87 and P/B of 0.59.
The outlook remains positive due to potential MGM acquisition interest and improving 2026 profitability projections, though risks include inconsistent earnings history and negative cash flow trends. Institutional sentiment is bullish with no sell ratings, supporting near-term upside potential if acquisition talks materialize.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
